1. Home
  2. WYY vs PLYX Comparison

WYY vs PLYX Comparison

Compare WYY & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo WidePoint Corporation

WYY

WidePoint Corporation

N/A

Current Price

$7.77

Market Cap

122.3M

Sector

Technology

ML Signal

N/A

Logo Polaryx Therapeutics Inc. Common Stock

PLYX

Polaryx Therapeutics Inc. Common Stock

N/A

Current Price

$1.97

Market Cap

112.7M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
WYY
PLYX
Founded
1991
2014
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
122.3M
112.7M
IPO Year
2005
2025

Fundamental Metrics

Financial Performance
Metric
WYY
PLYX
Price
$7.77
$1.97
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
★ $7.50
AVG Volume (30 Days)
★ 357.9K
22.2K
Earning Date
08-13-2026
11-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 77.53
EPS
★ 0.01
N/A
Revenue
★ $150,545,364.00
N/A
Revenue This Year
$12.26
N/A
Revenue Next Year
$25.66
N/A
P/E Ratio
$746.23
★ N/A
Revenue Growth
★ 5.59
N/A
52 Week Low
$3.96
$1.85
52 Week High
$24.30
$9.18

Technical Indicators

Market Signals
Indicator
WYY
PLYX
Relative Strength Index (RSI) 39.77 46.50
Support Level $4.46 $2.03
Resistance Level $12.69 $2.21
Average True Range (ATR) 1.23 0.10
MACD -0.46 0.00
Stochastic Oscillator 40.88 34.89

Price Performance

Historical Comparison
WYY
PLYX

About WYY WidePoint Corporation

WidePoint Corp is a provider of Technology Management as a Service (TMaaS) that consists of federally certified communications management, identity management, interactive bill presentment and analytics, and an Information Technology as a Service solution. Its solutions include Telecom Lifecycle Management, Digital billing communications solutions, and Mobile and Identity management. Geographically, the company generates a majority of its revenue from the United States and the rest from Europe.

About PLYX Polaryx Therapeutics Inc. Common Stock

Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.

Share on Social Networks: